Results 11 to 20 of about 37,793 (186)

Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions

Journal of Pharmacy & Pharmaceutical Sciences, 2021
Purpose: Remdesivir, a drug originally developed against Ebola virus, is currently recommended for patients hospitalized with coronavirus disease of 2019 (COVID-19).
Subrata Deb, Anthony Allen Reeves
doaj   +3 more sources

Interaction of Remdesivir with Clinically Relevant Hepatic Drug Uptake Transporters

Pharmaceutics, 2021
Remdesivir has been approved for treatment of COVID-19 and shortens the time to recovery in hospitalized patients. Drug transporters removing remdesivir from the circulation may reduce efficacy of treatment by lowering its plasma levels.
Anne T. Nies, Jörg König, Ute Hofmann, Charlotte Kölz, Martin F. Fromm, Matthias Schwab   +5 more
doaj   +3 more sources

Thorough QT/QTc Clinical Study to Evaluate the Effect of Remdesivir on Cardiac Repolarization in Healthy Participants. [PDF]

Clin Transl Sci
ABSTRACT QT interval prolongation associated with drug administration is an important consideration in drug development. Patients with COVID‐19 are at increased risk for cardiac complications, and QT interval prolongation correlates with higher mortality.
Peng CC, Duan R, Abdelghany M, Davies S, Xiao D, Kwan A, Ruiz-Garcia A.   +6 more
europepmc   +2 more sources

The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and meta-analysis

Therapeutic Advances in Drug Safety, 2021
Introduction: Remdesivir, an experimental antiviral drug has shown to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), both in vitro and in vivo .
Chenchula Santenna, Kota Vidyasagar, Krishna Chaitanya Amarneni, Sai Nikhila Ghanta, Balakrishnan Sadasivam, Saman Pathan, R. Padmavathi   +6 more
doaj   +1 more source

Co-Administration of Remdesivir and Azithromycin May Protect against Intensive Care Unit Admission in COVID-19 Pneumonia Requiring Hospitalization: A Real-Life Observational Study

Antibiotics, 2022
The benefits of remdesivir treatment, with or without co-administration of antibiotics such as azithromycin, are uncertain in COVID-19 pneumonia. The aim of this retrospective single-center study was to assess the effects of remdesivir, with or without ...
Andrea Ticinesi, Domenico Tuttolomondo, Antonio Nouvenne, Alberto Parise, Nicoletta Cerundolo, Beatrice Prati, Ilaria Zanichelli, Angela Guerra, Nicola Gaibazzi, Tiziana Meschi   +9 more
doaj   +1 more source

Remdesivir Strongly Binds to RNA-Dependent RNA Polymerase, Membrane Protein, and Main Protease of SARS-CoV-2: Indication From Molecular Modeling and Simulations

Frontiers in Pharmacology, 2021
Development of new drugs is a time-taking and expensive process. Comprehensive efforts are being made globally toward the search of therapeutics against SARS-CoV-2.
Faez Iqbal Khan, Tongzhou Kang, Haider Ali, Dakun Lai   +3 more
doaj   +1 more source

In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters

International Journal of Pharmaceutics: X, 2021
Remdesivir dry powder for inhalation was previously developed using thin film freezing (TFF). A single-dose 24-h pharmacokinetic study in hamsters demonstrated that pulmonary delivery of TFF remdesivir can achieve plasma remdesivir and GS-441524 levels ...
Sawittree Sahakijpijarn, Chaeho Moon, Zachary N. Warnken, Esther Y. Maier, Jennie E. DeVore, Dale J. Christensen, John J. Koleng, Robert O. Williams, III   +7 more
doaj   +1 more source

Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trials

Frontiers in Pharmacology, 2022
Since December 2019, COVID-19 has spread across the world almost through 2.5 years. As of 16 June 2022, the cumulative number of confirmed cases of COVID-19 worldwide has reached 542.62 million, and the death toll has risen to 6.33 million.
Zhenchao Wu, Zhenchao Wu, Zhifei Han, Zhifei Han, Beibei Liu, Beibei Liu, Ning Shen, Ning Shen   +7 more
doaj   +1 more source

The utility of remdesivir in SARS-CoV-2: A single tertiary care center experience from a developing country

Exploratory Research in Clinical and Social Pharmacy, 2022
Background: Remdesivir is a monophosphoramidate prodrug of an adenosine analog, and it has a broad-spectrum antiviral activity against paramyxoviruses, flaviviruses, and coronaviruses.
Muhammad Irfan Malik, Sardar Al Fareed Zafar, Muna Malik, Fabiha Qayyum, Iqra Akram, Ammarah Arshad, Khalid Waheed, Jodat Saleem, Abdul Jabbar, Muhammad Junaid Tahir, Zohaib Yousaf   +10 more
doaj   +1 more source

Remdesivir and Lopinavir/Ritonavir as Potential Drugs to Treat Corona Virus Disease 2019

, 2021
Drugs that are efficacious against SARS-CoV-2 have yet to be established. Remdesivir and Lopinavir/ritonavir have garnered considerable attention for their potential to treat coronavirus disease 2019 (COVID-19).
Sanaa Bouchnafati, Bouhmou Ayoub, Bzikha ilham, Reda Bzikha   +3 more
core   +1 more source